Nano Dimension Proposes Merger with Infinite Epigenetics
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Nano Dimension announced it has entered into a non-binding term sheet for a proposed business combination with Infinite Epigenetics. Under the term sheet, the proposed transaction contemplates that Nano Dimension, or a successor publicly traded company, would acquire 100% of the equity interests of Infinite Epigenetics through a merger, consolidation or other transaction structure to be mutually agreed by the parties. Upon closing of the proposed transaction, if any, the combined company is expected to operate under the Infinite Epigenetics name and continue trading on the Nasdaq Capital Market under the proposed ticker symbol (IEAI). Existing Nano Dimension shareholders are expected to retain a minority ownership interest in the combined company based on a stated value for Nano shares that reflects a 20% premium to Nano Dimension's estimated net cash at closing, subject to final negotiation and execution of a definitive agreement. The parties expect that the combined company will have over $400M in cash at closing. Additionally, the pre-combination Nano Dimension shareholders would receive a contingent value right entitling them to certain net proceeds, if any, received by a newly formed entity and liquidation trust from the disposition of certain Nano legacy assets following the closing of the combination. The term sheet provides for a 30-day period of mutual exclusivity, during which Nano Dimension will conduct confirmatory due diligence on Infinite Epigenetics, and the parties will finalize the terms of a definitive merger agreement. Matthew Dawson, co-founder and CEO of Infinite Epigenetics, is expected to serve as CEO of the combined company. The board is expected to include representatives designated by Nano, as well as Infinite Epigenetics leaders and directors. Nano Dimension expects to announce additional details regarding the proposed business combination if and when a definitive agreement is executed.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NNDM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NNDM
About NNDM
Nano Dimension Ltd, former ZBI Ltd, is an Israel-based company active in the technology sector. The Company operates as a provider of intelligent machines for the fabrication of Additively Manufactured Electronics (AME). Its portfolio solutions ranging from Additively Manufactured Electronics (AME), Printed Electronics (PE), Micro Additive Manufacturing, Artificial Intelligence (AI) deep learning, Surface-Mount Technology SMT Pick-and-Place, and inkjet solutions. Products portfolio consists products such as, DragonFly IV advanced 3D printing, Admatec 3D printers, AME materials, Versatile High Speed Dispensing Solutions, Production SMD software, Full Convection Reflow Ovens, Global Inkjet Systems, DeepCube, Fabrica 2.0 and Fabrica Micro-AM Materials among others. The Company targets a range of industry sectors, such as smart electronic devices that rely on printed circuit boards, connected devices, Radio Frequency (RF) components and antennas, sensors, and smart products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Nano Dimension and Infinite Epigenetics Provide Business Combination Update
- Transaction Details: Nano Dimension announced its plan to acquire Infinite Epigenetics for $890 million, a decision made after a rigorous strategic review of approximately 20 companies, highlighting the firm's commitment to the biotechnology sector and its growth potential.
- Shareholder Feedback Response: Despite significant shareholder Murchinson's opposition, labeling the deal as a 'poor business decision,' Nano Dimension emphasized its intention to engage with shareholders to ensure comprehensive understanding before finalizing the transaction.
- Value Creation Opportunity: Nano Dimension noted that Infinite Epigenetics possesses a CLIA-certified methylation laboratory and defensible proprietary assets, indicating that this merger is not merely a capital deployment but a strategic plan aimed at creating long-term value for shareholders.
- Tense Shareholder Relations: This transaction occurs against a backdrop of longstanding tensions between Nano Dimension and Murchinson, who previously attempted to replace three directors, illustrating the complexities and challenges within the company's governance structure.
See More
Nano Dimension and Infinite Epigenetics Merger Update
- Merger Progress: The merger between Nano Dimension and Infinite Epigenetics is actively being negotiated, with the company committed to transparent communication with shareholders to ensure all stakeholders understand the potential value of the transaction, despite final details still being under discussion.
- Scientific Foundation and Market Potential: Infinite Epigenetics boasts a database of over 120,000 biological samples and a CLIA-certified laboratory capable of processing over one million epigenetic signals, demonstrating its strong commercial potential in molecular diagnostics, which is expected to drive long-term value creation for Nano.
- Capital Deployment Plan: Nano Dimension plans to deploy capital to accelerate Infinite's commercialization efforts, expanding its provider network and test volume while developing its biological AI platform to enable earlier detection of chronic diseases, which is anticipated to significantly enhance the company's competitiveness in the health diagnostics market.
- Shareholder Interest Protection: The merger transaction will provide Nano's shareholders with a 20% premium on the cash value, with the board committed to not supporting any arrangements that do not align with shareholder interests, ensuring that shareholders retain corresponding rights in the combined company.
See More
Nano Dimension Proposes Merger with Infinite Epigenetics for Long-Term Value Creation
- Strategic Review Outcome: Nano Dimension conducted a multi-month strategic review assessing approximately 20 companies, ultimately selecting Infinite Epigenetics as the most compelling path for long-term value creation, demonstrating its strategic vision in the healthcare AI sector.
- Transaction Value and Shareholder Benefits: The proposed transaction is valued at $890 million, with existing Nano shareholders expected to retain meaningful minority ownership in the combined company, reflecting a 20% premium over Nano's estimated net cash, ensuring maximized shareholder interests.
- Market Opportunity and Technological Edge: Infinite Epigenetics targets a $90 billion U.S. clinical diagnostics market, leveraging its extensive private epigenetic dataset and proprietary biological AI platform to provide earlier disease risk warnings, showcasing significant market potential.
- Future Outlook and Leadership Team: Post-merger, Infinite Epigenetics' CEO Matthew Dawson will continue to lead the new company, expected to utilize Nano's capital base and Nasdaq listing platform to accelerate its mission in the high-growth healthcare AI space.
See More
Murchinson Warns Nano Dimension Shareholders on Board Decisions
- Shareholder Warning: Murchinson Ltd., a significant shareholder with approximately 7.4% of Nano Dimension's shares, publicly expresses concerns about the Board's decisions, suggesting they may prioritize self-preservation over shareholder interests, indicating deep dissatisfaction with corporate governance.
- Historical Lessons: Murchinson highlights the similarities between current Chairman Bob Pons and former Chairman Yoav Stern, who allegedly led the company into value-destructive transactions, raising questions about the transparency of the Board's decision-making and potentially undermining investor confidence.
- Industry Selection Concerns: Murchinson expresses skepticism about the sectors the Board may consider, such as space exploration, AI, and medical technology, arguing that these trendy choices may not align with the company's long-term interests and could lead to capital loss.
- Shareholder Engagement Invitation: Murchinson invites other shareholders to share their views on the Board's decisions and predict potential executive compensation, demonstrating a commitment to influencing the Board's direction through collective shareholder voices.
See More
Stratasys Acquires MarkForged for $42.5M
- Acquisition Agreement: Stratasys has entered into a definitive agreement to acquire MarkForged, a wholly owned subsidiary of Nano Dimension, in an all-cash transaction valued at $42.5 million, expected to close in the second half of 2026, thereby enhancing Stratasys' capabilities in the aerospace and defense sectors.
- Revenue Contribution: MarkForged generated approximately $70 million in revenue in 2025, and while its Metal Binder Jetting product line will be retained by Nano Dimension, this acquisition will provide Stratasys with new distribution channels, enhancing its competitive position in the market.
- Positive Market Reaction: Following the announcement of the acquisition, Stratasys' stock rose by 1.9% in premarket trading, indicating investor optimism regarding the deal and its potential to bolster the company's long-term growth prospects.
- Future Guidance: Stratasys stated it would update its financial guidance following the completion of the transaction, reflecting the company's confidence in future performance and its strategic intent to expand in a rapidly evolving market landscape.
See More
Nano Dimension Sells MarkForged to Reduce Cash Burn by $15 Million
- Strategic Progress: Nano Dimension has announced the sale of its wholly-owned subsidiary MarkForged for $42.5 million in cash, marking a significant step in its three-phase strategic plan aimed at enhancing long-term shareholder value through business simplification and balance sheet strengthening.
- Cash Burn Reduction: The transaction is expected to reduce annualized cash burn by approximately $15 million, primarily achieved through direct and indirect operating cost savings, thereby enhancing the company's financial flexibility and supporting future growth.
- Product Line Retention: Despite the sale of MarkForged, Nano Dimension will retain the Markforged Metal Binder Jetting product line, a decision that not only ensures the continued development of core technologies but also lays the groundwork for future market opportunities.
- Future Outlook: The transaction is expected to close in the second half of 2026, as Nano Dimension continues to advance its strategic plan and actively seeks strategic opportunities with potential partners to maximize long-term shareholder value.
See More
Nano Dimension and Infinite Epigenetics Provide Business Combination Update
- Transaction Details: Nano Dimension announced its plan to acquire Infinite Epigenetics for $890 million, a decision made after a rigorous strategic review of approximately 20 companies, highlighting the firm's commitment to the biotechnology sector and its growth potential.
- Shareholder Feedback Response: Despite significant shareholder Murchinson's opposition, labeling the deal as a 'poor business decision,' Nano Dimension emphasized its intention to engage with shareholders to ensure comprehensive understanding before finalizing the transaction.
- Value Creation Opportunity: Nano Dimension noted that Infinite Epigenetics possesses a CLIA-certified methylation laboratory and defensible proprietary assets, indicating that this merger is not merely a capital deployment but a strategic plan aimed at creating long-term value for shareholders.
- Tense Shareholder Relations: This transaction occurs against a backdrop of longstanding tensions between Nano Dimension and Murchinson, who previously attempted to replace three directors, illustrating the complexities and challenges within the company's governance structure.
See More
Nano Dimension and Infinite Epigenetics Merger Update
- Merger Progress: The merger between Nano Dimension and Infinite Epigenetics is actively being negotiated, with the company committed to transparent communication with shareholders to ensure all stakeholders understand the potential value of the transaction, despite final details still being under discussion.
- Scientific Foundation and Market Potential: Infinite Epigenetics boasts a database of over 120,000 biological samples and a CLIA-certified laboratory capable of processing over one million epigenetic signals, demonstrating its strong commercial potential in molecular diagnostics, which is expected to drive long-term value creation for Nano.
- Capital Deployment Plan: Nano Dimension plans to deploy capital to accelerate Infinite's commercialization efforts, expanding its provider network and test volume while developing its biological AI platform to enable earlier detection of chronic diseases, which is anticipated to significantly enhance the company's competitiveness in the health diagnostics market.
- Shareholder Interest Protection: The merger transaction will provide Nano's shareholders with a 20% premium on the cash value, with the board committed to not supporting any arrangements that do not align with shareholder interests, ensuring that shareholders retain corresponding rights in the combined company.
See More
Nano Dimension Proposes Merger with Infinite Epigenetics for Long-Term Value Creation
- Strategic Review Outcome: Nano Dimension conducted a multi-month strategic review assessing approximately 20 companies, ultimately selecting Infinite Epigenetics as the most compelling path for long-term value creation, demonstrating its strategic vision in the healthcare AI sector.
- Transaction Value and Shareholder Benefits: The proposed transaction is valued at $890 million, with existing Nano shareholders expected to retain meaningful minority ownership in the combined company, reflecting a 20% premium over Nano's estimated net cash, ensuring maximized shareholder interests.
- Market Opportunity and Technological Edge: Infinite Epigenetics targets a $90 billion U.S. clinical diagnostics market, leveraging its extensive private epigenetic dataset and proprietary biological AI platform to provide earlier disease risk warnings, showcasing significant market potential.
- Future Outlook and Leadership Team: Post-merger, Infinite Epigenetics' CEO Matthew Dawson will continue to lead the new company, expected to utilize Nano's capital base and Nasdaq listing platform to accelerate its mission in the high-growth healthcare AI space.
See More
Murchinson Warns Nano Dimension Shareholders on Board Decisions
- Shareholder Warning: Murchinson Ltd., a significant shareholder with approximately 7.4% of Nano Dimension's shares, publicly expresses concerns about the Board's decisions, suggesting they may prioritize self-preservation over shareholder interests, indicating deep dissatisfaction with corporate governance.
- Historical Lessons: Murchinson highlights the similarities between current Chairman Bob Pons and former Chairman Yoav Stern, who allegedly led the company into value-destructive transactions, raising questions about the transparency of the Board's decision-making and potentially undermining investor confidence.
- Industry Selection Concerns: Murchinson expresses skepticism about the sectors the Board may consider, such as space exploration, AI, and medical technology, arguing that these trendy choices may not align with the company's long-term interests and could lead to capital loss.
- Shareholder Engagement Invitation: Murchinson invites other shareholders to share their views on the Board's decisions and predict potential executive compensation, demonstrating a commitment to influencing the Board's direction through collective shareholder voices.
See More
Stratasys Acquires MarkForged for $42.5M
- Acquisition Agreement: Stratasys has entered into a definitive agreement to acquire MarkForged, a wholly owned subsidiary of Nano Dimension, in an all-cash transaction valued at $42.5 million, expected to close in the second half of 2026, thereby enhancing Stratasys' capabilities in the aerospace and defense sectors.
- Revenue Contribution: MarkForged generated approximately $70 million in revenue in 2025, and while its Metal Binder Jetting product line will be retained by Nano Dimension, this acquisition will provide Stratasys with new distribution channels, enhancing its competitive position in the market.
- Positive Market Reaction: Following the announcement of the acquisition, Stratasys' stock rose by 1.9% in premarket trading, indicating investor optimism regarding the deal and its potential to bolster the company's long-term growth prospects.
- Future Guidance: Stratasys stated it would update its financial guidance following the completion of the transaction, reflecting the company's confidence in future performance and its strategic intent to expand in a rapidly evolving market landscape.
See More
Nano Dimension Sells MarkForged to Reduce Cash Burn by $15 Million
- Strategic Progress: Nano Dimension has announced the sale of its wholly-owned subsidiary MarkForged for $42.5 million in cash, marking a significant step in its three-phase strategic plan aimed at enhancing long-term shareholder value through business simplification and balance sheet strengthening.
- Cash Burn Reduction: The transaction is expected to reduce annualized cash burn by approximately $15 million, primarily achieved through direct and indirect operating cost savings, thereby enhancing the company's financial flexibility and supporting future growth.
- Product Line Retention: Despite the sale of MarkForged, Nano Dimension will retain the Markforged Metal Binder Jetting product line, a decision that not only ensures the continued development of core technologies but also lays the groundwork for future market opportunities.
- Future Outlook: The transaction is expected to close in the second half of 2026, as Nano Dimension continues to advance its strategic plan and actively seeks strategic opportunities with potential partners to maximize long-term shareholder value.
See More
